Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
V512
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Intramuscular
01
Overview
**V512** is Merck's investigational bivalent influenza peptide-conjugate vaccine, also termed BIPCV/IMX. It contains peptide antigens derived from influenza A matrix protein 2 and influenza B hemagglutinin precursor, formulated with a Merck aluminum adjuvant and the saponin-based ISCOMATRIX adjuvant. The vaccine was evaluated to induce immune responses and support prevention of influenza infection in healthy adults in a completed Phase 1 dose-escalation and dose-ranging study. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT00851266))
- Other names
- BIPCV/IMX
02
Targets
M2e (Influenza A matrix protein 2 ectodomain)HA0 (Influenza B virus hemagglutinin)CHRM2 (M2)HA (Hemagglutinin)
Beyond the preview
Go deeper on V512.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on V512.